Lilly announces plans to build $5 billion manufacturing facility in Virginia
Eli Lilly (NYSE:LLY) has announced plans to construct a $5 billion manufacturing facility in Goochland County, Virginia, marking the first of four planned U.S. manufacturing sites to be announced this year. The facility will be the company's first dedicated, fully integrated site for producing active pharmaceutical ingredients (API) and drug products for bioconjugates and monoclonal antibodies.
The project will create 650 high-paying permanent jobs and 1,800 construction jobs, with completion expected within five years. The facility will focus on manufacturing antibody-drug conjugates (ADCs) and is part of Lilly's $50 billion U.S. capital expansion commitment since 2020. For every dollar invested, the company expects to generate up to four dollars in local economic activity.
Eli Lilly (NYSE:LLY) ha annunciato piani per costruire un impianto di produzione da 5 miliardi di dollari nella contea di Goochland, in Virginia, segnando il primo di quattro impianti statunitensi pianificati per quest'anno. L'impianto sarà il primo sito dedicato e completamente integrato per produrre principi attivi (API) e prodotti farmaceutici per bioconiugati e anticorpi monoclonali.
Il progetto creerà 650 posti di lavoro permanenti ben retribuiti e 1.800 posti di lavoro in fase di costruzione, con completamento previsto entro cinque anni. L'impianto si concentrerà sulla produzione di coniugati anticorpo-farmaco (ADC) e fa parte dell'impegno di Lilly di espandere il capitale statunitense di 50 miliardi di dollari dal 2020. Per ogni dollaro investito, l'azienda prevede di generare fino a quattro dollari di attività economica locale.
Eli Lilly (NYSE:LLY) ha anunciado planes para construir una instalación de fabricación de 5.000 millones de dólares en el condado de Goochland, Virginia, marcando el primero de cuatro sitios de fabricación en EE. UU. que se anunciarán este año. La instalación será el primer sitio dedicado e totalmente integrado para producir ingredientes farmacéuticos activos (API) y productos farmacéuticos para bioconjugados y anticuerpos monoclonales.
El proyecto creará 650 empleos permanentes bien remunerados y 1.800 empleos de construcción, con completarse en cinco años. La instalación se centrará en la fabricación de conjugados anticuerpo-fármaco (ADC) y forma parte del compromiso de Lilly de expansión de capital en EE. UU. por 50.000 millones de dólares desde 2020. Por cada dólar invertido, la empresa espera generar hasta cuatro dólares en actividad económica local.
Eli Lilly (NYSE:LLY)는 버지니아주 구치랜드 카운티에 50억 달러 규모의 제조 시설를 건설하는 계획을 발표했으며, 올해 발표될 미국 내 4개 제조 사이트 중 첫 번째가 됩니다. 이 시설은 생물결합물과 단일클론 항체를 위한 활성 의약품 원료(API) 및 의약품을 생산하는 최초의 전용 전통적 통합 현장입니다.
이 프로젝트로 6백50개의 고임금 고용 안정직 및 1,800개의 건설 직이 창출되며, 5년 내 완공이 예상됩니다. 이 시설은 항체-의약품 결합제(ADC) 생산에 중점을 두며 2020년 이래 Lilly의 미국 내 500억 달러의 자본 확장 약속의 일부입니다. 투자액 1달러당 지역 경제 활동이 최대 4달러까지 창출될 것으로 회사는 기대합니다.
Eli Lilly (NYSE:LLY) a annoncé des plans de construction d'une installation de fabrication de 5 milliards de dollars dans le comté de Goochland, Virginie, marquant le premier de quatre sites de fabrication américains prévus cette année. L'installation sera le premier site dédié et entièrement intégré pour produire des matières premières pharmaceutiques actives (API) et des produits médicamenteux pour les bioconjugués et les anticorps monoclonaux.
Le projet créera 650 emplois permanents bien rémunérés et 1 800 emplois de construction, avec une achèvement prévu dans cinq ans. L'installation se concentrera sur la fabrication de conjugués anticorps-médicament (ADC) et fait partie de l'engagement de Lilly d'investir 50 milliards de dollars dans l'expansion du capital américain depuis 2020. Pour chaque dollar investi, l'entreprise prévoit de générer jusqu'à quatre dollars d'activité économique locale.
Eli Lilly (NYSE:LLY) hat Pläne angekündigt, eine 5-Milliarden-Dollar-Fertigungsanlage im Goochland County, Virginia, zu errichten. Damit markiert es den ersten von vier geplanten US-Standorten, die in diesem Jahr angekündigt werden. Die Anlage wird die erste spezialisierte, vollständig integrierte Produktionsstätte des Unternehmens für aktive pharmazeutische Wirkstoffe (API) und Arzneimittelprodukte für Biokonjugate und monoklonale Antikörper sein.
Das Projekt schafft 650 gut bezahlte Festanstellungen und 1.800 Arbeitsplätze im Bau, mit einer Fertigstellung innerhalb von fünf Jahren. Die Anlage wird sich auf die Herstellung von Antikörper-Wirkstoff-Konjugaten (ADC) konzentrieren und ist Teil von Lillys 50-Milliarden-Dollar-US-Kapitalexpansion-Verpflichtung seit 2020. Für jeden investierten Dollar rechnet das Unternehmen damit, bis zu vier Dollar an lokaler Wirtschaftsaktivität zu generieren.
إيلي ليلي (شركة NYSE: LLY) أعلنت عن خطط لبناء مرفق تصنيع بقيمة 5 مليارات دولار في مقاطعة غووتش لاند بولاية فرجينيا، وهو الأول من أربعة مواقع تصنيع أميركية مخطط لها هذا العام. سيكون المرفق أول موقع مخصص ومتكامل تماماً لإنتاج المكونات الصيدلانية النشطة (API) ومنتجات دوائية للمركبات الحيوية وال antibodies أحادية النسيلة.
سيخلق المشروع 650 وظيفة دائمة عالية الأجر و 1,800 وظيفة بناء، ومن المتوقع الانتهاء خلال خمس سنوات. سيركز المرفق على تصنيع مركبات مضاد الجسم-دواء (ADC) وهو جزء من التزام Lilly بتوسيع رأس المال الأميركي بقيمة 50 مليار دولار منذ 2020. مقابل كل دولار مستثمر، تتوقع الشركة أن تولد حتى أربعة دولارات من النشاط الاقتصادي المحلي.
礼来公司（NYSE:LLY）宣布计划在弗吉尼亚州古奇兰县打造一座价值50亿美元的制造基地，这是今年公布的四个计划中的首个美国制造基地。该基地将是公司首个专门、全链条整合的用于生产活性药物成分(API)和生物偶联药物及单克隆抗体药物的场所。
该项目将创造 650个高薪永久岗位和 1,800个建筑岗位，预计五年内完工。该基地将聚焦生产抗体药物偶联物（ADC），并成为自2020年以来礼来在美国资本扩张承诺的一部分，金额为500亿美元。每投资一美元，公司预计可产生多达四美元的当地经济活动。
- Major $5 billion investment demonstrates strong financial commitment to U.S. manufacturing expansion
- Creation of 650 high-paying permanent jobs and 1,800 construction positions
- Expected 4x economic multiplier effect on local economy for every dollar invested
- Part of larger $50 billion U.S. capital expansion commitment since 2020
- Strategic expansion into advanced bioconjugate and monoclonal antibody manufacturing
- Significant capital expenditure of $5 billion may impact short-term cash reserves
- Five-year completion timeline indicates delayed return on investment
- Substantial operational costs associated with running a fully integrated manufacturing facility
Insights
Lilly's $5B Virginia facility strengthens U.S. manufacturing capacity for advanced therapies while creating jobs and establishing domestic bioconjugate production.
Eli Lilly's announcement of a
The investment is particularly significant as it addresses the growing importance of antibody-drug conjugates (ADCs) in Lilly's portfolio. ADCs represent one of the most promising therapeutic approaches in oncology and potentially autoimmune diseases, combining the targeting precision of antibodies with potent cytotoxic payloads. By establishing dedicated domestic manufacturing for these complex biologics, Lilly is securing greater control over a critical segment of its development pipeline.
From a supply chain perspective, this facility helps Lilly reduce dependence on external manufacturing partners or overseas facilities for specialized biologics production. The investment is part of a broader
The economic impact extends beyond Lilly's operations, with projections suggesting each dollar invested will generate up to four dollars in local economic activity. The facility will create 650 high-skill jobs plus 1,800 construction positions, with manufacturing roles supporting additional positions in adjacent industries. The implementation of advanced technologies like AI and machine learning in manufacturing processes demonstrates Lilly's commitment to modernizing pharmaceutical production.
This investment effectively positions Lilly to meet growing demand for its specialized biologics while strengthening domestic pharmaceutical manufacturing capabilities – a strategic priority highlighted during recent supply chain disruptions.
New site in
Company will create 2,450 high-wage manufacturing and construction jobs
This marks the first of four new
Earlier this year, at a press conference in
An ADC is a targeted therapy designed to deliver potent medicines directly to diseased cells. By combining the precision of monoclonal antibodies with the power of cytotoxic medicines, ADCs can act like highly specialized carriers, maximizing treatment effectiveness while reducing harm to healthy tissue. They are primarily used to treat cancer but are being explored for autoimmune diseases and other conditions.
"Our investment in
Expected to be completed within the next five years, the manufacturing site will bring more than 650 new high-paying jobs to
Lilly's capital investment and jobs numbers announced today go beyond what the company initially committed to in the
"Lilly is one of the world's great innovators, and I want to thank them for this significant commitment to
Lilly will use advanced technologies such as machine learning, AI and automated systems at the site. This will enable right-first-time execution, all in support of the safe and reliable supply of medicines. To maximize the latest technology, digital integrations and automation, the company plans to engage locally, partnering with local universities and supporting community educational initiatives in
"This isn't just another manufacturing site — it represents a significant milestone for Lilly, as we begin building our first bioconjugate facility," said Edgardo Hernandez, executive vice president and president of Lilly Manufacturing Operations. "With this cutting-edge site, Lilly is setting a new benchmark in bioconjugate innovation, advancing technologies that will expand what's possible for patients. This investment reflects our bold vision, our commitment to transformative technologies and our dedication to being a good neighbor through sustainability efforts and support of local education and community partnerships."
The company plans to announce the three remaining
Support for Lilly's job creation will be provided, in part, through the Virginia Talent Accelerator Program. The program was created by the Virginia Economic Development Partnership in collaboration with higher education partners.
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. C-LLY
Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) including about planned capital investments in new manufacturing capacity, certain medical treatments, economic impact of investment, production of medicines, hiring and related initiatives and reflects Lilly's current beliefs and expectations. However, as with any such undertaking, there are substantial risks and uncertainties in the manufacturing process, development and commercialization of pharmaceutical products any of which could impact the overall commercial success of our products, and as related to cost, completion timing, expected capacity, personnel, and other factors which could impact expected benefits of the capacity expansion and related initiatives. For further discussion of risks and uncertainties relevant to Lilly's business that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.
Refer to: Carla Cox; cox_carla@lilly.com; 317-750-3923 (Media)
Michael Czapar; czapar_michael_c@lilly.com; 317-617-0983 (Investors)
View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-announces-plans-to-build-5-billion-manufacturing-facility-in-virginia-302556880.html
SOURCE Eli Lilly and Company
FAQ
What is the cost and location of Lilly's new manufacturing facility?
How many jobs will Lilly's new Virginia facility create?
What will Lilly manufacture at the new Virginia facility?
When will Lilly's Virginia manufacturing facility be completed?
How many new U.S. manufacturing sites is Lilly planning to build?
What is the economic impact of Lilly's new Virginia facility?
